Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Waqas Malick, Ori Waksman, Ron Do, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 16, pp. 1646-1658
Open Access | Times Cited: 20

Showing 20 citing articles:

Expanding the triglyceride range in clinical trials: therapeutic opportunities
Ask T. Nordestgaard, Aruna D. Pradhan, Brendan M. Everett, et al.
European Heart Journal (2025)
Closed Access | Times Cited: 4
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study
Zhongchen Li, Chunyu Yu, Heng Zhang, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Triglyceride-rich lipoproteins and cardiovascular diseases
Dandan Xu, Lin Xie, Cheng Cheng, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access | Times Cited: 1
Severe hypertriglyceridemia: Existing and emerging therapies
Waqas Malick, Ron Do, Robert S. Rosenson
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108544-108544
Closed Access | Times Cited: 17
Remnant cholesterol and low-grade inflammation jointly in atherosclerotic cardiovascular disease: implications for clinical trials
Daniel Elías-López, Takahito Doi, Børge G. Nordestgaard, et al.
Current Opinion in Clinical Nutrition & Metabolic Care (2023) Vol. 27, Iss. 2, pp. 125-135
Closed Access | Times Cited: 16
Apolipoprotein C3: form begets function
Karin Bornfeldt
Journal of Lipid Research (2023) Vol. 65, Iss. 1, pp. 100475-100475
Open Access | Times Cited: 14
The Novel Lipid-Based Chronic Disease Model in Lifestyle Medicine: Impact on Prevention of Atherosclerotic Cardiovascular Disease
Waqas Malick, Robert S. Rosenson, Ishan Naidu, et al.
Lifestyle Medicine (2025), pp. 75-102
Closed Access
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
Qingcong Zheng, Rongjie Lin, Du Wang, et al.
BMC Musculoskeletal Disorders (2025) Vol. 26, Iss. 1
Open Access
Emerging agents targeting triglycerides
Y. S. Prakash, Deepak L. Bhatt, Waqas Malick
Current Opinion in Lipidology (2025)
Closed Access
Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies
Gerald F. Watts, Dick C. Chan
European Heart Journal (2025)
Closed Access
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Madelyn Hurwitz, O. Agboola, Abhishek Gami, et al.
US Cardiology Review (2025) Vol. 19
Open Access
Target Populations for Novel Triglyceride-Lowering Therapies
Ask T. Nordestgaard, Anne Tybjærg‐Hansen, Hank Mansbach, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 19, pp. 1876-1897
Closed Access
How to Handle Elevated Triglycerides: Life after PROMINENT
Angela Pirillo, Alberico L. Catapano
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 12, pp. 921-929
Closed Access | Times Cited: 8
Hypertriglyceridemia and Multiorgan Disease Among U.S. Adults
Chen Gurevitz, Ligong Chen, Paul Muntner, et al.
JACC Advances (2024) Vol. 3, Iss. 5, pp. 100932-100932
Open Access | Times Cited: 3
Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: CGPS
Daniel Elías-López, Signe Vedel‐Krogh, Camilla J. Kobylecki, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 12, pp. 2647-2658
Closed Access | Times Cited: 3
An anti-PCSK9 pill a day to keep cholesterol away: next steps?
Gerald F. Watts
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 151-153
Closed Access | Times Cited: 2
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Yajnavalka Banerjee, Angelo Maria Patti, Rosaria Vincenza Giglio, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 8, pp. 108517-108517
Closed Access | Times Cited: 6
Triglyceride to high-density lipoprotein cholesterol ratio associated with long-term adverse clinical outcomes in patients deferred revascularization following fractional flow reserve
Fanqi Li, Xiaofang Li, Jiabao Zhou, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Temporal Trends in Lipoprotein(a) Testing Among United States Veterans from 2014-2023
Sofia Gomez, Adam Furst, Tania Chen, et al.
American Journal of Preventive Cardiology (2024) Vol. 20, pp. 100872-100872
Open Access | Times Cited: 1
Triglyceride to high-density lipoprotein cholesterol ratio associated with long-term adverse clinical outcomes in patients deferred revascularization following fractional flow reserve
Fanqi Li
Research Square (Research Square) (2024)
Open Access
Page 1

Scroll to top